Evaluating the role of opioid medication assisted therapies in HIV-1 Persistence
- Study HIC#:2000023013
- Last Updated:01/01/0001
The purpose of this study is to develop ways to examine how HIV stays in your body after someone starts medication assisted therapy (MAT) (e.g. buprenorphine/naloxone, buprenorphine, methadone or extended-release naltrexone), for the treatment of opioid use disorder, and to see how different types of MAT changes how HIV in the body.
The researchers will follow all participants and schedule regular interviews and blood draws to gather information. This will enable them to look at the presence of specific factors associated with HIV and treatment for opioid use disorder over time. The study will last for 3 months.
- Age18 years and older
- GenderBoth
Contact Us
For more information about this study, including how to volunteer, contact:
Victor Neirinckx
Help Us Discover!
You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call +18779788343 for more information.
Trial Purpose and Description
To develop methods to examine HIV-1 expression, proviral landscape and genomic architecture in response to different forms of MAT. To examine how different forms MAT changes HIV-1 persistence using viral and host genome mapping.
Eligibility Criteria
The researchers will follow all participants and schedule regular interviews and blood draws to gather information. This will enable them to look at the presence of specific factors associated with HIV and treatment for opioid use disorder over time. The study will last for 3 months.
Eligibility Criteria:
a) Have a problem with opioids (heroin or prescription pain medications)
b) starting medication assisted therapy (MAT) for your opioid use disorder (buprenorphine/naloxone, buprenorphine, methadone or extended-release naltrexone)
c) have HIV; and
d) you are 18 years of age or older.
No healthy volunteers
